charm program: 3 component trials comparing candesartan with placebo
DESCRIPTION
CHARM Program: 3 Component trials comparing candesartan with placebo. CHARM Program: Baseline characteristics. CHARM Program: Baseline medications. CHARM-Overall: CV death and non-CV death. CHARM Program: Reduction in mortality and morbidity. CHARM Program: Reduction in CHF hospitalization. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/1.jpg)
CHARM Program: 3 Component trials comparing candesartan with placebo
![Page 2: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/2.jpg)
CHARM Program: Baseline characteristics
![Page 3: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/3.jpg)
CHARM Program: Baseline medications
![Page 4: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/4.jpg)
CHARM-Overall: CV death and non-CV death
![Page 5: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/5.jpg)
CHARM Program: Reduction in mortality and morbidity
![Page 6: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/6.jpg)
CHARM Program: Reduction in CHF hospitalization
![Page 7: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/7.jpg)
CHARM-Preserved: Hospital admissions for CHF
![Page 8: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/8.jpg)
CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis
![Page 9: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/9.jpg)
CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis (cont’d)
![Page 10: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/10.jpg)
CHARM-Added: Effect of combined ACE inhibitor/-blocker/AT1-receptor blocker
![Page 11: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/11.jpg)
CHARM-Overall: Drug discontinuations for adverse events
![Page 12: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/12.jpg)
CHARM: Clinical implications
![Page 13: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/13.jpg)
CHARM-Overall: Reduction in new-onset diabetes
![Page 14: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/14.jpg)
CHARM: Impact of treatment
![Page 15: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/15.jpg)
HF with preserved LV systolic function in the elderly: Impact on survival
![Page 16: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/16.jpg)
CHARM-Preserved: CV death or CHF hospitalization
![Page 17: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/17.jpg)
CHARM-Preserved: Primary and secondary outcomes
![Page 18: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/18.jpg)
CHARM-Preserved: Clinical implications
![Page 19: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/19.jpg)
VALIANT: Design
![Page 20: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/20.jpg)
VALIANT: Concomitant medications
![Page 21: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/21.jpg)
VALIANT: Treatments show similar effect on outcome
![Page 22: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/22.jpg)
VALIANT: Clinical implications
![Page 23: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/23.jpg)
VALIANT: Effect of treatment on mortality—Subgroup analysis
![Page 24: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/24.jpg)
RESOLVD: Comparative impact of ACE inhibitor, ARB, and -blocker alone or combined on LVEF
![Page 25: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/25.jpg)
Differences in dosing among ARB trials
![Page 26: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/26.jpg)
Survival studies of -blockade in HF
![Page 27: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/27.jpg)
-Blockers improve survival in diabetic patients with HF: A meta-analysis
![Page 28: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/28.jpg)
MERIT-HF: -Blockade improves survival in CHF
![Page 29: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/29.jpg)
MERIT-HF: -Blockade improves survival in post-MI patients with HF
![Page 30: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/30.jpg)
MERIT-HF: Subgroup analysis in post-MI patients with HF (LVEF <25%)
![Page 31: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/31.jpg)
SOLVD: Heart rate predicts progression of asymptomatic LV dysfunction
![Page 32: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/32.jpg)
MERIT-HF: Effect of -blockade on heart rate
![Page 33: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/33.jpg)
MERIT-HF: -Blockade decreases mortality and hospitalization independent of resting heart rate
![Page 34: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/34.jpg)
CHRISTMAS: Design
![Page 35: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/35.jpg)
CHRISTMAS: Trial profile
![Page 36: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/36.jpg)
CHRISTMAS: Change in LVEF according to number of segments affected by myocardial hibernation
![Page 37: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/37.jpg)
COMET: Trial profile
![Page 38: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/38.jpg)
COMET: All-cause mortality
![Page 39: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/39.jpg)
COMET: Heart rate at each visit
![Page 40: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/40.jpg)
COMET: Blood pressure
![Page 41: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/41.jpg)
-Blocker HF trials: Mortality results
![Page 42: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/42.jpg)
Mortality rates in perspective CIBIS-II, MERIT-HF, COMET
![Page 43: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/43.jpg)
Immediate-release vs sustained release metoprolol: Significant pharmacokinetic differences
![Page 44: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/44.jpg)
COMET: Clinical implications
![Page 45: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/45.jpg)
Comparison of -blocker effects in major HF trials
![Page 46: CHARM Program: 3 Component trials comparing candesartan with placebo](https://reader035.vdocuments.mx/reader035/viewer/2022062518/56814799550346895db4cde3/html5/thumbnails/46.jpg)
Not all -blockers are the same